Featured Story | By Max Bayer Biohaven reported that troriluzole has failed a phase 3 trial in spinocerebellar ataxia, just weeks after CEO Vlad Coric, M.D., touted the company's future as a slimmed-down R&D engine after the migraine business was sold off to Pfizer for $11.6 billion. read more |
| |
|---|
|
| Sponsored by: Agilex Biolabs Bioanalytical Laboratory Offers Qualified U.S. Clients a 43.5% Cash Rebate for Conducting Studies in its Australia-based FDA-Inspected Labs read more |
| |
|---|
|
|  | TREM Proteins: Emerging Targets of Immunotherapy TREM proteins are promising targets in neurodegenerative diseases, inflammatory diseases and cancers. Sino Biological has developed a panel of recombinant TREM protein and antibody reagents to support the study of the biology of this protein family. Learn more. |
Top Stories By Nick Paul Taylor Concert Pharmaceuticals has hit the high notes in a phase 3 alopecia areata clinical trial, finding 41.5% of people had at least 80% scalp hair coverage after taking the high dose of its JAK inhibitor. The data put Concert in the wings as Eli Lilly and Pfizer prepare to take to the stage and compete for the market. read more By Annalee Armstrong Fierce Biotech is once again seeking your nominations for the best, most exciting and innovative private biotechs. read more By Nick Paul Taylor Johnson & Johnson’s $230 million blood pressure bet has hit the mark in phase 3. Idorsia-partnered aprocitentan significantly reduced blood pressure in patients with resistant hypertension, although the rate of fluid retention and initial lack of detail on efficacy leave scope to question whether it will live up to its blockbuster billing. read more By Gabrielle Masson Holding company Innoviva is acquiring late-stage antibiotic biotech Entasis Therapeutics, a 2015 AstraZeneca spin-out that just posted phase 3 results worthy of an FDA filing last year. read more By Gabrielle Masson A Cleveland Clinic-led research team discovered how tumors evade prostate cancer therapy and identified a short timespan in which hard-to-treat tumors may respond to treatment, opening the door—or window—to potential new strategies. read more By Eric Sagonowsky,Annalee Armstrong,Max Bayer,Angus Liu As the biopharma industry develops increasingly specialized treatments, regulators are being forced to adapt. And at the same time, the industry is making strides toward becoming more inclusive. These are the most influential regulators and advocates in biopharma. read more By Andrea Park In the first year since Philips began taking precautions against a suspected safety issue with many of its ventilators and CPAP and BiPAP machines last April, the issue has sparked more than 21,000 complaints including reports of cancer, pneumonia, asthma, infection, headache, nodules, and chest pain as well as more than 120 deaths. read more By Robert King Mayo Clinic posted a $227 million net operating loss for the first quarter of 2022 as the system faced major headwinds from rising labor expenses to a volatile investment market. read more By Angus Liu An unusual wave of monkeypox cases in non-endemic regions has raised the possibility of another global health crisis. But two groups of biopharma experts argue monkeypox likely won’t escalate into another pandemic that humans struggle to contain. read more By Conor Hale Vibrant Gastro is putting forward its novel approach as a completely drug-free alternative to treatments for infrequent or difficult bowel movements. read more By Zoey Becker A week after getting the FDA go-ahead for a booster in the 5 to 11 age group, Pfizer and BioNTech revealed positive data from a booster trial of their COVID vaccine in younger children. The companies plan to add the new data to their rolling emergency use authorization submission this week. read more Resources Sponsored by: Catalent In this executive summary, we describe the benefits of controlled release, look at how to determine whether a drug is suitable for controlled release, review the application of PBPK modelling in controlled release formulation development and discuss how modified release products can be developed to deliver optimal patient outcomes. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored by: Blue Matter, strategic consultants in the life sciences Recent trends are driving big changes in Medical Affairs. This paper explores why, and what MA teams can do to stay ahead of the curve. Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. | 
